BioSpace News Archive

Teleflex Incorporated, a leading global provider of medical technologies for critical care and surgery, has been awarded group purchasing agreements for Central Venous Access and Arterial Access with Premier, effective July 1.

Wellgistics Wholesale has earned Drug Distributor reaccreditation from the National Association of Boards of Pharmacy® for another three-year term.

New guidance from the American Academy of Neurology concludes that closure of a common heart defect called a patent foramen ovale may be recommended for some people who have had a stroke.

The U.S. Food and Drug Administration announced the following actions taken in its ongoing response effort to the COVID-19 pandemic

In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1), researchers from The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery division and Ipsen Biopharmaceuticals reported the preclinical discovery and early-stage clinical development of this novel drug.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”) is pleased to announce new data are scheduled to be presented in two poster presentations during the American Society of Clinical Oncology’s (ASCO) Annual Meeting, a leading global scientific meeting for oncology professionals, taking place from 29 May – 31 May 2020

A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

ARTES Biotechnology, the German-based biotech company specializing in process development for recombinant vaccines, entered development of SARS-CoV-2 vaccine candidates based on its virus-like particle (VLP) based platform technologies METAVAX® and SplitCore.

The collaboration will begin with the development of a CDx-IVD for larotrectinib for the Chinese market. Larotrectinib is the world’s first TRK inhibitor to be approved in patients with TRK gene fusion cancer in all solid tumors in the United States (2018) and Europe (2019)

Vanda Pharmaceuticals Inc. announced it will release results for the first quarter 2020 on Wednesday, May 6, 2020, after the market closes.